| Ilyse Lifton, MD | |
|
12607 Se Mill Plain Blvd, Vancouver, WA 98684-6055 | |
| (360) 256-7104 | |
| Not Available |
| Full Name | Ilyse Lifton |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 12607 Se Mill Plain Blvd, Vancouver, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134214117 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD00044749 (Washington) | Primary |
| 208000000X | Pediatrics | MD25907 (Oregon) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Ilyse Lifton, MD 12607 Se Mill Plain Blvd, Vancouver, WA 98684-6055 Ph: () - | Ilyse Lifton, MD 12607 Se Mill Plain Blvd, Vancouver, WA 98684-6055 Ph: (360) 256-7104 |
News Archive
The Scottish Medicines Consortium, which advises NHS Scotland on prescribing new treatments, announced today that XTANDI (enzalutamide) is accepted for unrestricted use within NHS Scotland for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.
The physical forces that guide how cells migrate-how they manage to get from place to place in a coordinated fashion inside the living body- are poorly understood. Scientists at the Harvard School of Public Health and the Institute for Bioengineering of Catalonia have, for the first time, devised a way to measure these forces during collective cellular migration.
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).
Researchers have found that deep brain stimulation by sending in electric shocks to a part of the brain that plays a key role in memory improved people's ability to learn. This could raise hope for patients of Alzheimer's.
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, announced today that it is terminating its previously announced proposed public offering pursuant to a preliminary prospectus supplement and an effective shelf registration statement on file with the Securities and Exchange Commission due to market conditions.
› Verified 2 days ago
Aidan H Derenne, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 505 Ne 87th Ave, Ste 120, Vancouver, WA 98664 Phone: 360-892-1635 Fax: 360-892-3146 | |
Charles E Fuchs, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 505 Ne 87th Ave, Ste 120, Vancouver, WA 98664 Phone: 360-892-1635 Fax: 360-892-3146 | |
Laurie Metzger, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 700 Ne 87th Ave, Vancouver, WA 98664 Phone: 360-397-1500 Fax: 360-397-1328 | |
Jing Jing Wang, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 700 Ne 87th Ave, Vancouver, WA 98664 Phone: 360-882-2778 Fax: 360-604-1758 | |
Veronica S Erhart, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 6100 Ne Fourth Plain Blvd, Vancouver, WA 98661 Phone: 360-891-7300 | |
Katherine Elizabeth Holland, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 505 Ne 87th Ave, Suite 120, Vancouver, WA 98664 Phone: 360-892-1635 Fax: 360-892-3146 | |
Jennifer L Soden, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 505 Ne 87th Ave, Ste 120, Vancouver, WA 98664 Phone: 360-892-1635 Fax: 360-892-3146 |